Oculis Holding Ag · NASDAQ:OCS
Oculis — Shareholder Meeting (May 2026)
11 slides from Oculis's shareholder meeting presentation, May 13, 2026
Slide 1: Visionary Innovation – Annual General Meeting
Visionary Innovation Annual General Meeting May 13, 2026
Slide 2: Safe Harbor Statements
Safe Harbor Statements Cautionary note on forward-looking statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “i
Slide 3: Business Update
usiness Update Oculis
Slide 4: Successful 2025 Powering Transformative 2026
Successful 2025 Powering Transformative 2026 Pipeline: Significant advancements across all three late-stage assets OCS-01 DIAMOND Phase 3 program >800 patients with DME; Focused execution and on-track for topline readout in June Licaminlimab precision medicine approach for DED gained FDA align
Slide 5: Topline Results from Both DIAMOND Phase 3 Trials Expected in June 2026
Topline Results from Both DIAMOND Phase 3 Trials Expected in June 2026 OCS-01 NDA submission approval Q4 2027 for DME anticipated OCS-01 NDA submission Q4 2026 for DME planned DIAMOND Phase 3 trials topline results June 2026 in DME anticipated Last patient visit completed in April 2026 DIAMOND Phase
Slide 6: Privosegtor in Global Registrational PIONEER Program in Optic Neuropathies
Privosegtor, a Breakthrough Therapy and PRIME Designated Candidate, in Global Registrational PIONEER Program in Optic Neuropathies MS relapses IND submission 2H 2026 planned PIONEER-3 in NAION mid 2026 initiation anticipated Three Registrational trials in optic neuritis and NAION PIONEER-2 in optic
Slide 7: Pipeline Development and Strategic Evolution: Expand, Advance, Explore
Oculis Pipeline Development Strategic Evolution Explore Expand Potential for Privosegtor in multiple additional Privosegtor in Advance neuro-ophthalmology and beyond neuro-axonal diseases OCS-01 would be the first ever topical treatment in DME, if • NAION approved • MS relapses Licaminlimab precisio
Slide 8: A Catalyst-rich 12-month Horizon Driven by Three Core Transformative Assets
A Catalyst-rich 12-month Horizon Driven by Three Core Transformative Assets in Active Registrational Programs Candidate Phase 1 Phase 2 Phase 3 Value Catalysts OPHTHALMOLOGY OCS-01 DIAMOND-1 & DIAMOND-2 topline readout June 2026 OPTIREACH® Diabetic Macular Edema NDA submission for DME in Q4 2026 Sta
Slide 9: Financial Update
ancial Update Oculis
Slide 10: 2025 Key Financial Highlights
2025 Key Financial Highlights • Cash Position: held cash equivalents and short-term investments of CHF 213.0 million ($268.7 million), compared to CHF 98.7 million ($109.0 million) as of December 31, 2024. Increase primarily due to equity financings gross proceeds of $210.0 million (CHF 178.9 millio
Slide 11: Thank you
Ocu li 1S | vey,